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Brain Volume Changes After Withdrawal of Atypical
Antipsychotics in Patients With First-Episode Schizophrenia
Geartsje Boonstra, MD, MSc,*Þ Neeltje E.M. van Haren, PhD,* Hugo G. Schnack, PhD,*
Wiepke Cahn, MD, PhD,* Huibert Burger, MD, PhD,Þþ Maria Boersma, MSc,* Bart de Kroon, MSc,*
Diederick E. Grobbee, MD, PhD,Þ Hilleke E. Hulshoff Pol, PhD,* and Rene´ S. Kahn, MD, PhD*
Abstract: The inﬂuence of antipsychotic medication on brain mor-
phology in schizophrenia may confound interpretation of brain changes
over time. We aimed to assess the effect of discontinuation of atypical
antipsychotic medication on change in brain volume in patients. Sixteen
remitted, stable patients with ﬁrst-episode schizophrenia, schizoaffective
or schizophreniform disorder and 20 healthy controls were included.
Two magnetic resonance imaging brain scans were obtained from all
subjects with a 1-year interval. The patients either discontinued (n = 8)
their atypical antipsychotic medication (olanzapine, risperidone, or
quetiapine) or did not (n = 8) discontinue during the follow-up period.
Intracranial volume and volumes of total brain, cerebral gray and white
matter, cerebellum, third and lateral ventricle, nucleus caudatus, nucleus
accumbens, and putamen were obtained. Multiple linear regression
analyses were used to assess main effects for group (patient-control) and
discontinuation (yes-no) for brain volume (change) while correcting for
age, sex, and intracranial volume. Decrease in cerebral gray matter and
caudate nucleus volume over time was signiﬁcantly more pronounced
in patients relative to controls. Our data suggest decreases in the nucleus
accumbens and putamen volumes during the interval in patients who
discontinued antipsychotic medication, whereas increases were found
in patients who continued their antipsychotics. We conﬁrmed earlier
ﬁndings of excessive gray matter volume decrements in patients with
schizophrenia compared with normal controls. We found evidence sug-
gestive of decreasing volumes of the putamen and nucleus accumbens
over time after discontinuation of medication. This might suggest that
discontinuation reverses effects of atypical medication.
Key Words: antipsychotic agents, magnetic resonance imaging,
schizophrenia, follow-up studies, withholding treatment
(J Clin Psychopharmacol 2011;31: 146Y153)
Schizophrenia is a chronic disorder characterized by recurrentpsychotic episodes and a decline in functioning. Treatment
typically involves long-term antipsychotic use.
Increasing evidence suggests that the often replicated brain
volume decrease in schizophrenia1 is progressive over time.2Y7
Although some of the progressive brain changes seem related to
the course of illness,2,7Y11 it has been an issue of debate what,
if any, is the inﬂuence of medication. Some argue, based on
research in monkeys, that the loss of gray matter in schizo-
phrenia can be attributed to the use of typical or atypical anti-
psychotic medication.12 In contrast, in studies in patients with
schizophrenia, the loss of gray matter (GM) volume seems to be
attenuated by atypical antipsychotics but not by haloperidol.13Y15
One of the best replicated ﬁndings in schizophrenia is the
increase in caudate nucleus (NC) volume being related to the
intake of typical antipsychotics.16,17 It has been suggested that
changing treatment to atypical antipsychotics seems to ‘‘nor-
malize’’ this effect.18Y20 However, investigated longitudinally,
the use of atypical antipsychotic medication has been related to
stable,21Y23 increasing,22,24 and decreasing18,19,25Y27 volumes of
basal ganglia.
Differentiating between antipsychotic-induced changes and
those inherent to the disease would be most valid through ran-
domization of antipsychotic-naive ﬁrst-episode patients to
treatment or placebo in comparison with healthy controls.
However, this design is clearly coupled with ethical issues. One
alternative design is to longitudinally study brain volumes in
patients who discontinue their medication, or not. Guidelines
offer the psychiatrist the possibility to discontinue antipsychotic
medication in remitted and stable patients with ﬁrst-episode
schizophrenia.28 The National Institute for Health and Clini-
cal Excellence guideline29 states that ‘‘it is uncertain whether
maintenance drug treatment is required for all people with
schizophrenia. Around 20% of individuals will only experi-
ence a single episode’’. To assess medication-related changes
in brain volume over time, we compared remitted and stable
patients with schizophrenia in whom atypical antipsychotic
medication was either discontinued or continued in a 1-year
follow-up magnetic resonance imaging (MRI) study.
MATERIALS AND METHODS
Subjects
After complete description of the study, written informed
consent was obtained from all participants. The Medical Ethics
Review Board of the University Medical Center Utrecht ap-
proved the study. Sixteen patients were included. They were
aged 16 to 55 years and diagnosed with schizophrenia, schizo-
phreniform, or schizoaffective disorder as assessed with the
Structured Clinical Interview for Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition Axis-I disorders
(1996). They were treated in a tertiary or secondary psychiatric
center in The Netherlands. Furthermore, only clinically remitted
and stable ﬁrst-episode patients with scores of 3 or less over the
previous year on each core psychosis item (delusions, concep-
tual disorganization, hallucinatory behavior, and suspiciousness
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or persecution) of the Positive and Negative Syndrome Scale
(PANSS)30 were included. Exclusion criteria were medication
noncompliance during the past year, use of mood stabilizers,
severe neurological illness, current suicidal ideation, or a his-
tory of a serious suicide attempt. Duration of remission, suici-
dal ideation, and compliance were assessed by interviewing
patients and their treating physician. Of the included patients,
brain MR images were acquired at baseline (T0) and at 12
months’ follow-up (T12) or, if possible, at relapse before T12 and
before medication restart. To assess the inﬂuence of discontinua-
tion of atypical antipsychotics on brain volume change (corrected
for time interval: [volume T12 j volume T0]/[T12 j T0]), the
included patients were divided in 2 subgroups: patients who tapered
(in 6Y12 weeks) and discontinued antipsychotic treatment (n = 8)
and patients who continued antipsychotics (n = 8) between T0
and T12. A proportion of the participating patients (n = 10) was
selected from a randomized trial investigating the effect of dis-
continuation versus continuation of antipsychotics on relapse
risk (First author, accepted for publication). Half of the patients
in this study were originally randomized to continuation (n = 4)
or discontinuation (n = 4) and remained in that group. Two
patients in the discontinuation group were originally randomized
to continuation but tapered and discontinued after 6 months in
the study. The remainder of the patients (n = 6) chose to continue
or discontinue their antipsychotics. All subjects participating in
this study were on atypical antipsychotic medication at inclusion.
The type of drug had been determined by the treating physician,
and not the researcher, and remained the responsibility of the
treating physician during the study. In retrospect, none of the
patients changed their type of antipsychotic medication during
the current study. During follow-up, the patients were evaluated
every 2 months by a trained researcher, with extra visits in case
of impending relapse. In each visit, the PANSS was administered
and medication status was assessed. Haloperidol dose equiv-
alences (HEQ) for quantiﬁcation of antipsychotic exposure were
calculated using patient charts as follows (ratio haloperidolYother
antipsychotic): risperidone, 1:1; olanzapine, 1:2.5; quetiapine
1:100.31
In addition, 20 controls were included and scanned twice
with an interval of an average of 1 year. The controls were group
matched for age and sex to the patients. The control sample has
been described previously.2 Baseline characteristics are shown in
Table 1. The controls had no mental (history) or physical illness
at both baseline and follow-up measurements.
MRI Data Acquisition
Magnetic resonance images (MRIs) were acquired using a
1.5-T Philips NT scanner. AT1-weighted 3-dimensional (3D) fast
ﬁeld echo (echo time [TE], 4.6 milliseconds; repetition time
[TR], 30 milliseconds; ﬂip angle, 30 degrees; ﬁeld of view [FOV],
256/80%mm) with 160 to 180 contiguous coronal 1.2-mm slices,
and a T2-weighted dual echo turbo spin echo (TE1, 14 milli-
seconds; TE2, 80 milliseconds; TR, 6350 milliseconds; ﬂip angle,
90 degrees; FOV, 256/80% mm) with 120 contiguous coronal
1.6-mm slices of the whole head were used for the quantita-
tive measurements. In addition, a T2-weighted DE-TSE (Dual
TABLE 1. Baseline Characteristics of Normal Controls (NCS), All Patients (PTS), Patients Who Were Medication-Free at
Follow-Up (OFF), and Patients on Medication at Follow-Up (ON)
Variables, N or Mean (SD) NCS PTS P PTS OFF PTS ON P
Sex, male/female 15/5 12/4 n.s. 6/2 6/2 n.s.
Age, y 27.97 (5.63) 28.8 (6.9) n.s. 27.97 (8.24) 29.56 (5.72) n.s.
Handedness (right/left/both hands) 16/4/0 13/2/1 n.s. 7/1/0 6/1/1 n.s.
Patients’ level of education, y 14.40 (2.30) 12.94 (2.49) n.s. 13.75 (2.12) 12.13 (2.70) n.s.
Parental level of education, y 12.60 (2.14) 12.13 (3.00) n.s. 13.93 (1.84) 10.56 (3.02) 0.02
Diagnosis: schizophrenia/schizoaffective/
schizofreniform
8/6/2 4/3/1 4/3/1 n.s.
Scan interval, wk 53.76 (5.09) 55.63 (6.11) n.s. 57.27 (8.55) 54.00 (0.84) n.s.
Age at onset of illness, y 25.49 (7.04) 25.84 (8.16) 25.14 (6.27) n.s.
Antipsychotic taken during interval
olanzapine/risperidone/quetiapine
11/3/2 6/2/0 5/1/2 n.s.
Duration of psychosis before remission, y 1.19 (1.87) 0.96 (1.26) 1.42 (2.41) 0.02
Dosage of antipsychotics in H-EQ 3.38 (2.39) 3.50 (2.00) 3.25 (2.87) n.s.
H-EQ taken during interval corrected for
interval duration
856.55 (863.85) 547.37 (548.28) 1156.73 (1039.22) 0.005
Drugs/alcohol abuse or dependency ever
before T0 (no/yes)
19/1 8/8 n.s. 4/4 4/4 n.s.
Drugs/alcohol abuse/dependence at T0
(no/yes)
17/3 14/2 0.03 7/1 7/1 n.s.
PANSS
Positive scale 10.13 (2.66) 9.00 (1.60) 11.25 (3.11) n.s.
Negative scale 12.75 (3.15) 13.13 (3.72) 12.38 (2.67) n.s.
General scale 24.69 (5.34) 23.75 (2.61) 25.63 (7.23) n.s.
GAF 61.31 (11.61) 58.13 (11.93) 64.50 (11.11) n.s.
CGI 1.56 (0.63) 1.38 (0.52) 1.75 (0.71) n.s.
All differences for baseline characteristics were checked with the Pearson W2 test for nominal variables, analysis of variance for normally distributed
continuous variables, and Mann-Whitney U test for not normally distributed continuous variables.
CGI indicates Clinical Global Impression; GAF, Global Assessment of Functioning; H-EQ, haloperidol equivalents; n.s., nonsigniﬁcant; PANSS,
Positive and Negative Syndrome scale.
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Echo-Turbo Spin Echo) (TE1, 9 milliseconds; TE2, 100 milli-
seconds; TR, 2200 milliseconds; ﬂip angle, 90 degrees; FOV,
250/100% mm) with 17 axial 5-mm slices and 1.2-mm gap of
the whole head was acquired for clinical neurodiagnostic eval-
uation. The scans were processed on the neuroimaging com-
puter network of the Department of Psychiatry at the University
Medical Center Utrecht. Before quantitative assessments, 10 ran-
domly chosen images were cloned for calculation of interrater
reliability using the intraclass correlation coefﬁcient (ICC). All
images were coded to ensure blindness for subject identiﬁca-
tion. Scans were put into a Talairach frame (no scaling)32 and
corrected for inhomogeneities in the magnetic ﬁeld.33
Volume measures of the intracranium, total brain (TB), ce-
rebral gray (GM) and white matter (WM), cerebellum, and third
(V3) and lateral ventricles (LV) were determined. Quantitative
assessment of the intracranial volume was performed with the
use of a fully automated computer program based on histogram
analyses followed by mathematical morphological operators
in the DE-TSE image. Quantitative assessment of the TB, GM,
WM, cerebellar, V3, and LV volumes were performed based on
histogram analyses, followed by mathematical morphological
operators in the 3D fast ﬁeld echo image, using the intracranial
volume as mask.34,35 In addition, for the cerebellum and V3
and LV volumes, anatomical knowledge-based selection prin-
ciples were used. For the cerebellum, this included a plane per-
pendicular to the sagittal plane through the aqueduct. For the
V3, this included the coronal slices through the anterior com-
missure (AC) as anterior border, the coronal slice through the
posterior commissure as posterior border, and a manually out-
lined roof to prevent leaks into the transverse cistern, drawn in
the midsagittal reconstructed slice from a point superior to the
thalamus and just inferior to the plexus choroideus. For the LVs,
this included automated computer-incorporated anatomical
knowledge of the anatomical location of the LVs in the brain (eg,
they are surrounded by WM). All segmentations were checked
after measurements and corrected manually if necessary. The in-
terrater reliabilities of the volume measurements, determined by
the ICC, were 0.95 and higher.
Basal ganglia structures were traced manually by a single
experienced rater (B.K.). Nucleus caudatus (NC), putamen, and
nucleus accumbens (NA) were outlined in contiguous coronal
slices in an anterior-posterior direction. The sagittal and axial
planes were used for reference. Segmentation procedures are
based on previously described guidelines.18,36
In the ﬁrst segmentation slice, the NC had to be visible
inferolateral of the LVs; in the last slice, either the posterior
commissure appeared or the NC was still clearly discernible in
the coronal view. Medially, the frontal horn and body of the LV
bordered the NC and, laterally, the internal capsule. The inter-
connecting GM striae between the NC and putamen visible in the
internal capsule were not included in the NC or putamen volumes.
At the inferior border, the CA and the NA were separated by a
horizontal line from the most basal extent of the LV to the most
lateral point of the NC.
Putamen segmentation commenced in the ﬁrst slice where
the structure was clearly distinguishable, and it ended in the last
slice where the boundaries were still clearly discernible. The
anterior limb of the internal capsule and the globus pallidus
formed the medial border and the external capsule the lateral
border. Inferomedially, the putamen and the NA were separated
by a vertical line from the most lateroinferior point of the internal
capsule to the inferior border of the putamen/NA. In slices where
the AC was visible, the most lateral point of the AC was used
as the starting point of the vertical line separating the putamen
and the NA.
In the ﬁrst slice containing both NC and putamen, seg-
mentation of the NA started, and it ended in the slice where the
boundaries for the NA were still clearly discernible. Supero-
laterally, the putamen and NC bordered the NA, and inferome-
dially, they bordered the surrounding WM.
Ten scans were duplicated and randomly intermixed with
the data set to allow for an estimation of intrarater reliability
using ICCs. Intraclass correlation coefﬁcient scores were 0.99
for NC, 0.97 for NA, and 0.90 for putamen volume.
Data Analysis
To investigate the effect of illness and antipsychotic treat-
ment on brain volume (change) multiple linear regression anal-
yses were performed using SPSS 15. Volumes of the total brain,
cerebral GM and WM, LV, V3, nucleus accumbens, nucleus
caudatus, and putamen were added as dependent variable. A
group variable (patient/control) and a medication variable (on/off
medication at follow-up) were added as independent variables.
Age, intracranial volume, and sex were added as covariates. In
case of signiﬁcant group differences in (change in) basal ganglia
volumes, baseline TB volume instead of the intracranial volume
was added as a covariate. In addition, it was tested if baseline
volume of the basal ganglia structures were correlated with
volume change over time using Pearson correlations. If this
were the case, baseline volume was added as a covariate.
As the patients and controls differed signiﬁcantly on abuse
of drugs and/or alcohol at baseline and the patient groups dif-
fered signiﬁcantly on parental education, these variables were
added separately as a covariate in case of signiﬁcant ﬁndings.
This will only be mentioned if it led to differences in the results.
The patient groups also differed signiﬁcantly on duration
of illness since the ﬁrst start of antipsychotics, but because of
the high correlations with age (r = 0.92, P G 0.001), adding this
as a covariate will lead to the problem of multicollinearity. All
statistical tests were 2-tailed. For the comparisons of volume
(change) between the 2 patient groups, conﬁdence interval, range,
and median were given for signiﬁcant results.
RESULTS
Demographic and Clinical Comparison of Groups
Baseline characteristics were comparable between the
patients and the controls and between the patient groups. There
were 4 exceptions (Table 1; Data Analysis section 2.3). The 1-year




At baseline V3 and putamen, the volume of patients was
signiﬁcantly larger than that of the controls (Table 2). The vol-
ume at V3 remained larger after exclusion of one outlier. Cor-
rection for TB instead of intracranial volume did not change
these results.
Change
Gray matter and NC volume changes during the interval
differed signiﬁcantly between patients and controls (Table 3;
Fig. 1, A and D). Whereas the controls showed an increase in
GM and NC volumes, the patients showed decreases over time.
In addition, the NA volume increase over time was more pro-
nounced in the controls compared to that in the patients (Table 3;
Fig. 1C). Furthermore, the WM volume in the patients’ group
showed a larger increase over time compared to that of the
controls (Table 3; Fig. 1B). The signiﬁcant changes in the basal
Boonstra et al Journal of Clinical Psychopharmacology & Volume 31, Number 2, April 2011
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ganglia remained signiﬁcant after correction for the baseline TB
volume and the baseline volume of the structure concerned.
However, after exclusion of the largest outlier in the patients, the
difference in the NA change was not signiﬁcant (P = 0.18), and
after correction for having a positive history of alcohol or drug
abuse or dependency, the difference in the NA change was trend-
level signiﬁcant (P = 0.06).
Medication Effect
The 2 patient groups did not differ signiﬁcantly on any of
the volumes at baseline except for the putamen volume (Table 2;
b = j1.49; 95% CI, j2.23 to j0.74); discontinuation group:
range (8.52Y13.12), median (10.07); continuation group: range
(6.75Y11.08), median (8.88).
Over time, a decrease in NA and putamen volumes was
found in patients who discontinued medication, whereas in-
creases were found in the patients who continued their anti-
psychotics (Table 3; Fig. 2, A and B; NA: b = 0.14; 95% CI,
0.01Y0.28; discontinuation group: range [j0.32 to 0.02], median
[j0.04]; continuation group: range [j0.09 to 0.33], median
[j0.07]; putamen: b = 0.77; 95% CI, 0.35Y1.20; discontinuation
group: range [j0.53 to 0.21], median [j0.03]; continuation
group: range [j0.29 to 1.93], median [0.49]). Correction for TB
volume did not change these ﬁndings. However, after exclusion
of the largest outlier in the patients, the difference in the NA
changes was no longer signiﬁcant (P = 0.12).
DISCUSSION
This study examined the effect of discontinuation of atyp-
ical antipsychotic medication on brain volume change during a
1-year interval in remitted and stable patients with ﬁrst-episode
schizophrenia. We replicated earlier ﬁndings of excessive de-
crease in cerebral GM volume in patients relative to controls. In
addition, our results suggest that discontinuation or continuation
of atypical antipsychotics does not inﬂuence GM volume change
FIGURE 1. One-year (raw) volume change in controls and patients for cerebral GM (A), cerebral white matter (B),
nucleus accumbens (C), and nucleus caudate (D).
FIGURE 2. One-year (raw) nucleus accumbens (A) and putamen (B) volume change in patients who either stopped or continued
antipsychotic treatment before a second MRI scan. Note the differences in range of the y-axis.
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in patients. If anything, cerebral GM volume decrease over time
seemed more pronounced in the patients who discontinued than
in those who continued antipsychotic medication, although this
difference was not signiﬁcant. Our results suggest that the ex-
cessive reduction of GM volume occurs irrespective of atypical
antipsychotic treatment continuation or discontinuation. This
might indicate that the excessive loss of GM volume in patients
with schizophrenia cannot be explained by the intake of atypical
antipsychotic medication.
To date, only a limited number of longitudinal studies have
been done that looked directly at the inﬂuence of atypical anti-
psychotic treatment on brain volume in a controlled manner.
This is especially the case if one excludes studies in which the
prestudy treatment was unknown and consisted of both atypical
and typical antipsychotics, or where patients were analyzed
together independently of being antipsychotic naive, or not, be-
fore the study.15,26,37Y44 Findings so far indicate that GM vol-
ume increases after starting atypical antipsychotic treatment in
antipsychotic-naive patients during a 4-week interval (although
no control group was available)2Y7 but also after changing from
typical to atypical antipsychotic treatment.14 One randomized
study identiﬁed GM loss after 1 year of treatment with haloper-
idol compared to olanzapine.15 Unfortunately, it was not men-
tioned what type of antipsychotics (typical/atypical) the patients
used before the start of the study medication. Together, these
ﬁndings suggest that atypical antipsychotics might prevent the
loss of GM tissue. Indeed, in a large longitudinal study in a
sample of both ﬁrst-episode and chronically ill patients, cumula-
tive intake of atypical medication was associated with less loss
of GM tissue.11
That GM tissue loss is most likely associated with the effects
of the illness, and is not a consequence of (atypical) antipsychotic
medication intake, is also supported by evidence that cerebral
GM deﬁcits in patients seem to be present before the start of
antipsychotic medication45Y48 or even before the start of the ﬁrst
symptoms.7 However, some studies report no differences between
normal controls and medication-naive patients.14,49Y52
In contrast to our ﬁndings in humans, a randomized study in
Macaque monkeys found that chronic treatment with atypical
(n = 6, for 1.2 years) and typical (n = 6, for 2.2 years) anti-
psychotics resulted in a reduction of parietal GM volume com-
pared with placebo.12 However, it is difﬁcult to extrapolate these
regional postmortem animal ﬁndings to those occurring in vivo
in the brains of patients with schizophrenia.
Antipsychotics may exert their effect in focal areas of the
brain.53 Here, we focused on the basal ganglia. At baseline, all
patients were on atypical antipsychotic medication. The patients
discontinuing atypical antipsychotics seemed to decrease in
NA and putamen volumes over time. This is of particular interest
inasmuch as the putamen volume seemed to increase in the
patients compared to the controls at baseline. Moreover, the 2
patient groups did not differ on baseline brain volumes, except
for the putamen, which was larger in the patients who dis-
continued their antipsychotic regimen compared to the patients
who continued their antipsychotic medication. Outcome of the
illness might be a possible explanation for this, as Buchsbaum
et al10 identiﬁed a larger putamen in patients with good outcome
of schizophrenia in comparison to those with a poor outcome
and healthy controls. Indeed, the patients who stopped tolerated
tapering and were able to not use medication without experi-
encing a relapse for a certain period of time. Whether this would
have been the case in those that continued their antipsychotics
is unknown.
It might be that the increase in putamen volume at baseline
in the patients relative to the controls is an effect of taking
atypical antipsychotic medication (although this cannot be tested
in our study, but see Glenthoj et al22). If this were the case, our
ﬁndings suggest that discontinuation reverses the effects of
atypical medication, at least in the putamen and possibly, to
some extent, in the NA.
Indeed, starting atypical antipsychotics in antipsychotic-
naive patients resulted in volume increases in the NC,24 NA,24 and
putamen22 compared to baseline22 or compared to the controls,24
although some studies found no volume changes.21,22,24 In con-
trast, starting atypical antipsychotics after discontinuing typical
antipsychotic medication has been associated with caudate18,25,27
and putamen volume reductions,19 whereas other studies found no
caudate19 or putamen volume change.27 These data imply that the
consequences of atypical medication are dependent on the state of
the brain, being medication-naive or being on typical medication.
Suggestive evidence was found for an excessive increase
over time in cerebral WM volume in the patients compared to the
controls, which, in the patients, did not seem to be inﬂuenced by
either continuation or discontinuation of antipsychotics. Cere-
bral WM volume in the antipsychotic-naive patients was re-
ported to be similar to the healthy controls14,46,49,51,52 (but for
decreased WM, see Chua et al45). Although the initiation of
atypical antipsychotics in antipsychotic-naive14 or antipsychotic-
free schizophrenia54 did not result in WM volume changes, WM
volume did decrease signiﬁcantly in haloperidol-treated patients
whose treatment was changed to clozapine.14
Strengths and Limitations
Studies like this one are complicated to carry out, resulting
in a small number of included patients. Consequently, type II
errors cannot be ruled out. To our knowledge, this is the ﬁrst
MRI study that compared brain volume change between patients
who discontinued or continued atypical antipsychotic medica-
tion. Therefore, we are convinced that, despite the small sample
size, it is important to present these data. In addition, this serves
as the rationale for not applying a correction for multiple testing.
Most of our ﬁndings would not have survived such a correction.
Half of the patients in this study were randomized to con-
tinuation (n = 4) or discontinuation (n = 4). In the continua-
tion group, the remaining 4 patients chose to continue their
medication because of fear of relapse, which is a sign of good
insight. In contrast, in the discontinuation group, 4 patients de-
cided to stop their antipsychotic treatment despite risk of relapse.
Because insight is a predictor of good outcome,55 the continu-
ation group might have consisted of patients with a better out-
come than the discontinuation group. However, all patients
were clinically stable enough to allow for discontinuation at
inclusion in the study.
In this study, the patients used olanzapine, risperidone, or
quetiapine, which are grouped among the atypical anti-
psychotics28 and have less binding potential for the D2 receptor
than typical antipsychotics.56 However, risperidone is known to
have a more ﬁrm grip on the D2 receptor than the other second-
generation antipsychotics.57Y59 This differential effect of binding
potential for the 3 antipsychotics used in this study might have
diluted the volume changes in the discontinuation group in the
basal ganglia structures.
The exclusion of more severe patients (at risk or with his-
tory of suicide, and abandonment of previous treatment) and the
inclusion of patients with a priori better prognosis than schizo-
phrenia such as schizoaffective disorder and schizophreniform
disorder, made this sample one with a better prognosis than the
general population of ﬁrst psychotic episodes, as indicated by
the values of the PANSS, the Global Assessment of Functioni-
ng, and the Clinical Global Impression at baseline. This is a
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consequence of the design of the study, as guidelines offer the
psychiatrist the possibility to discontinue antipsychotic medi-
cation only in remitted and stable patients with ﬁrst-episode
schizophrenia.28
CONCLUSIONS
We conﬁrmed earlier ﬁndings of GM volume decrements in
patients with schizophrenia in comparison to healthy controls.
Our main conclusion is that the excessive cerebral GM volume
decrease found in patients with schizophrenia is unlikely to be
explained by atypical antipsychotic treatment. However, the in-
crease in putamen volume at baseline seems to be (at least partly)
a medication effect as putamen (and also nucleus accumbens)
volume decreased in patients after discontinuation with atypical
antipsychotics.
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